eTheRNA immunotherapies

Please note: The information displayed on this page might be outdated.
eTheRNA immunotherapies: Developer of immunotherapies intended to offer targeted and safe mRNA therapies for the human immune system. The company's immunotherapies contain proprietary mRNA-based TriMix technology that boosts dendritic cells leading to a more comprehensive, sustainable, and safer enhancement of the patient's immune system than any other similar approach investigated, enabling healthcare providers to help patients fight cancer and other infectious diseases.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Listing
Private
Website:
Profiles:
Address:
Galileilaan 19
Niel, Brussels Hoofdstedelijk Gewest 2845
Belgium

Company Participants at European Biotech Investor Days 2021

Steven Powell
eTheRNA immunotherapies, CEO
Steven has acquired broad experience in several life-science sectors in R&D, corporate finance and commercial roles. He started his career with Beecham Pharmaceuticals (now GSK) and subsequently held senior roles with both public and private biotechnology and healthcare companies in Europe and North America. He was also a partner with a European venture capital fund.